Hybrid compositions for intracellular targeting
Patent 7335750 Issued on February 26, 2008. Estimated Expiration Date: 
November 18, 2022. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
November 18, 2022. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.Patent ReferencesHybrid compositions for intracellular targeting Patent #: 6482586 InventorsAssigneeApplicationNo. 10298408 filed on 11/18/2002US Classes:530/402, Chemical modification or the reaction product thereof, e.g., covalent attachment or coupling, etc.530/350, PROTEINS, I.E., MORE THAN 100 AMINO ACID RESIDUES536/23.1, DNA or RNA fragments or modified forms thereof (e.g., genes, etc.)536/24.5, Nucleic acid expression inhibitors435/69.1, Recombinant DNA technique included in method of making a protein or polypeptide435/325, ANIMAL CELL, PER SE (E.G., CELL LINES, ETC.); COMPOSITION THEREOF; PROCESS OF PROPAGATING, MAINTAINING OR PRESERVING AN ANIMAL CELL OR COMPOSITION THEREOF; PROCESS OF ISOLATING OR SEPARATING AN ANIMAL CELL OR COMPOSITION THEREOF; PROCESS OF PREPARING A COMPOSITION CONTAINING AN ANIMAL CELL; CULTURE MEDIA THEREFORE435/455, Introduction of a polynucleotide molecule into or rearrangement of nucleic acid within an animal cell435/471, Introduction of a polynucleotide molecule into or rearrangement of nucleic acid within a microorganism (e.g., bacteria, protozoa, bacteriophage, etc.)514/4, With an additional active ingredient514/44, Polynucleotide (e.g., RNA, DNA, etc.)435/4MEASURING OR TESTING PROCESS INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITION OR TEST STRIP THEREFORE; PROCESSES OF FORMING SUCH COMPOSITION OR TEST STRIPExaminersPrimary: Kaushal, SumeshAssistant: Burkhart, Michael Attorney, Agent or FirmInternational ClassesC07K 14/245C07H 21/02 C07H 21/04 A61K 38/16 A61K 31/7088 C12N 5/00 C12N 15/87 C12P 21/02 AbstractHybrid compounds comprising a first domain and a second domain are provided. The first domain and the second domain are preferably covalently linked, and the first domain comprises a domain which is capable of specific binding to Gb3; and the second domain comprising a moiety selected from the group consisting of drug moiety, a nucleic acid, a probe, a polypeptide, and a hook, with the proviso that the second domain is not a verotoxin or a fragment thereof. Methods of preparing and using the hybrid compounds are also provided. ClaimsWhat is claimed is: 1. A hybrid molecule comprising a first domain and a second domain covalently linked, wherein (a) said first domain comprises a domain which is capable of specific binding toglobotriaosylceramide, and wherein said first domain is a verotoxin or a B subunit of verotoxin; (b) said second domain comprises a nucleic acid. 2. The hybrid molecule of claim 1, wherein the first domain is a verotoxin. 3. The hybrid molecule of claim 1, wherein the first domain is a B subunit of verotoxin. 4. The hybrid molecule of claim 1, wherein the nucleic acid is an antisense nucleic acid. 5. A method for modulating a cell-associated activity, comprising contacting a cell with the hybrid molecule of claim 1 in vitro, such that a cell associated activity is altered relative to the cell-associated activity of the cell in theabsence of the hybrid molecule, wherein said nucleic acid modulates said cell-associated activity. 6. A hybrid molecule comprising a first domain and a second domain covalently linked, wherein (a) said first domain comprises a domain which is capable of specific binding to globotriaosylceramide, and wherein said first domain is a verotoxinor a B subunit of verotoxin; (b) said second domain comprises a polypeptide, wherein said polypeptide is a DNA binding element. 7. The hybrid molecule of claim 6, wherein the first domain is a verotoxin. 8. The hybrid molecule of claim 6, wherein the first domain is a B subunit of verotoxin. 9. A method for modulating a cell-associated activity comprising contacting a cell with the hybrid molecule of claim 6 in vitro, such that a cell associated activity is altered relative to the cell-associated activity of the cell in the absenceof the hybrid molecule, wherein said nucleic acid modulates said cell-associated activity. 10. The hybrid molecule of claim 1, wherein said nucleic acid is DNA, RNA, or a DNA/RNA chimeric nucleic acid. 11. The method of claim 5, wherein said cell associated activity is cell growth or replication. 12. The method of claim 5, wherein said cell associated activity is expression of an endogenous or exogenous gene product. 13. The method of claim 9, wherein said cell associated activity is cell growth or replication. 14. The method of claim 9, wherein said cell associated activity is expression of an endogenous or exogenous gene product. Other References
|
| ||||||||||||||
